Small:多管齐下,基于白蛋白的肿瘤多重响应性纳米药物

2017-05-28 佚名 MaterialsViews

响应性纳米药物在肿瘤治疗中具有重要价值。一方面,肿瘤响应性纳米药物通过对肿瘤组织和细胞的识别,降低药物对正常组织的毒副作用;另一方面通过在肿瘤中响应性释放药物,提高治疗效果。尤其是对于光动力治疗(PDT),纳米剂型中光敏剂的单线态氧产生能力受到抑制,无法发挥PDT的作用,必须在肿瘤组织或细胞中快速释放,恢复单线态氧的产生能力和对细胞的杀伤作用。与正常组织相比,肿瘤具备pH值偏低、谷胱甘肽(GSH)

响应性纳米药物在肿瘤治疗中具有重要价值。一方面,肿瘤响应性纳米药物通过对肿瘤组织和细胞的识别,降低药物对正常组织的毒副作用;另一方面通过在肿瘤中响应性释放药物,提高治疗效果。尤其是对于光动力治疗(PDT),纳米剂型中光敏剂的单线态氧产生能力受到抑制,无法发挥PDT的作用,必须在肿瘤组织或细胞中快速释放,恢复单线态氧的产生能力和对细胞的杀伤作用。与正常组织相比,肿瘤具备pH值偏低、谷胱甘肽(GSH)浓度升高、蛋白酶过表达的特性。基于肿瘤的这些特性,人们设计了诸多响应性的纳米药物,但这些纳米药物大多只对一种或两种刺激条件具备响应,或者响应条件苛刻,因而在抗肿瘤应用中的效果有待提高。如何在纳米药物的设计中合理利用肿瘤的特性,赋予纳米药物对肿瘤的特异性识别和响应,仍是有待解决的难点。

近期,中国科学院过程工程研究所闫学海研究团队设计了一种基于生物大分子自组装的肿瘤响应性纳米药物。在该纳米药物的构建过程中,首先由人血清白蛋白(HSA)和多聚赖氨酸在水体系中自组装形成纳米粒,再通过二硫苏糖醇打开白蛋白中的二硫键,并通过新生成的二硫键交联纳米粒,最后在纳米粒表面修饰一层PEG,得到稳定的纳米粒。这种纳米粒对多种光敏剂(Chlorin e6(Ce6)、protoporphyrin IX和verteporfin)均具有很好的负载作用,因而可构建纳米药物。由于自组装纳米粒中包含了HSA、二硫键和静电作用力,其结构对肿瘤微环境中存在的低pH值、GSH、蛋白酶具有响应性,而且对多重条件的响应具备联合增强效果。在体内实验中,当将含有Ce6的纳米药物分别注射到肿瘤组织和正常组织中时,肿瘤部位在0.5小时后就观察到了Ce6的荧光,而正常组织在8小时后才可观察到荧光。这是首次通过光学方法直接观察到纳米药物在肿瘤部位响应性释放药物。在尾静脉注射纳米药物的实验中,12个小时后药物在肿瘤出现特异性富集,而对照组没有观察到药物在肿瘤处的富集。注射纳米药物24小时后,以激光照射肿瘤,实现了对肿瘤的光动力消除,在实验的观察周期内没有发生肿瘤复发现象。该纳米药物的良好效果源于设计中的两大特点:仿生自然,利用了白蛋白的电荷转变特性及肿瘤对白蛋白的代谢增强机制;多管齐下,充分利用了肿瘤中存在的多重特异性条件。

该肿瘤多重响应性纳米药物的研究不仅为光动力抗肿瘤纳米药物的研发提供了新思路,也可有效应用于其他涉及肿瘤响应性的纳米药物的构建,如化疗药物递送、肿瘤诊断与成像等。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-30 珙桐
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-30 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-30 江川靖瑶
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-30 xugc
  6. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-29 luominglian113

    学习了涨知识了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-29 临风淑玉

    学习了,感谢分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1804612, encodeId=c99b1804612d2, content=<a href='/topic/show?id=20cae745155' target=_blank style='color:#2F92EE;'>#纳米药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77451, encryptionId=20cae745155, topicName=纳米药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Feb 02 16:47:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304596, encodeId=4479130459663, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328954, encodeId=f07f132895468, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388843, encodeId=00751388843ad, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475679, encodeId=bd6014e567972, content=<a href='/topic/show?id=cbcce745264' target=_blank style='color:#2F92EE;'>#纳米药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77452, encryptionId=cbcce745264, topicName=纳米药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a11c7248108, createdName=xugc, createdTime=Tue May 30 12:47:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204146, encodeId=9f9f204146d5, content=学习了涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon May 29 23:17:45 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204037, encodeId=feff20403ebd, content=学习了,感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon May 29 14:17:47 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203806, encodeId=729b20380619, content=学习了,非常好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon May 29 06:08:25 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-29 1e0f8808m18(暂无匿称)

    学习了,非常好的研究。

    0

相关资讯

根据白蛋白或肾功能衰竭校正苯妥英钠浓度计算公式

根据白蛋白或肾功能衰竭校正苯妥英钠浓度计算公式

PLoS One:急性缺血性卒中应用白蛋白的安全性分析

背景:先前研究显示白蛋白治疗缺血性卒中与心肺的不良事件相关,脑出血的发生率较低。研究人员在白蛋白与急性卒中的(ALIAS)第2部分多中心试验中旨在研究,应用白蛋白后神经系统和心肺不良事件的发生。方法:缺血性卒中的患者,年龄在18-83岁之间,基线NHISS ≥ 6,在卒中开始后5h内随机给予ALB治疗或生理盐水作为对照组治疗。神经系统不良事件包括症状性脑出血,偏侧颅骨肥大,神经功能恶化,神经细胞死

CIRC J:血清白蛋白和C反应蛋白对经皮冠状动脉介入治疗患者的远期结局的作用

之前研究报道炎症和营养不良与动脉粥样硬化,尤其是伴随慢性肾脏病的患者密切相关。本研究探讨了经皮冠状动脉介入术(PCI)后血清白蛋白和C反应蛋白(CRP)对临床疗效的综合影响。本研究纳入2000年至2011年间2,164例冠状动脉疾病患者首次进行PCI治疗,术前行血清白蛋白和hs-CRP水平检测得到相关数据。根据患者血清白蛋白和CRP水平(分别为4.1 g / dL和0.10 mg / dL)将其分

The Lancet Neurol:大剂量白蛋白治疗缺血性卒中试验未显示临床获益

研究要点: 1.大剂量白蛋白人体可安全耐受。 2.大剂量白蛋白对缺血性脑卒中未显示出临床获益。 缺血性卒中的动物模型显示,25%的白蛋白降低脑梗死体积并提高神经功能预后。之前的一项探索性临床研究显示,高达2g/kg的白蛋白剂量在安全剂量范围内。该研究的目的旨在评价在缺血性卒中起病5小时内给予白蛋白是否改善卒中的预后。 【原文阅读】 该研究为随机双盲平行组的3期安慰剂对照试验,纳入2009年

ESC 2013:白蛋白对急性卒中患者无益

  于第22届欧洲卒中大会(ESC2013)公布的急性卒中白蛋白治疗(ALIAS)3期研究表明,与应用盐水治疗相比,急性卒中患者应用白蛋白治疗无更多获益,且与较多的不良反应(肺水肿)相关。   研究的报告者Myron D. Ginsberg博士表示,虽然白蛋白被认为是一种有前景的治疗方法,但就像其他许多神经保护剂一样,它似乎只在动物中起作用而非在人类中。在前期的临床前研究中,

白蛋白结合紫杉醇治疗胆管癌初见成效

胆管癌症是最具侵略性肿瘤之一,迄今为止可用的医疗治疗方法受到很大限制。目前MedUni Vienna and Vienna General Hospital临床肿瘤学家证实白蛋白结合紫杉醇(nab-paclitaxel)可以非常有效的对抗胆管癌症。 研究发现白蛋白结合紫杉醇可以在胆管癌症治疗中使用,延长了患者的生命。在奥地利,每年有不到800人罹患胆管癌(胆管细胞癌),患者平均生存期为一年左右。